The global cancer biomarkers market size reached US$ 24.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 53.7 Billion by 2028, exhibiting a growth rate (CAGR) of 12.95% during 2023-2028. More Info:- https://www.imarcgroup.com/cancer-biomarkers-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Cancer Biomarkers
Market Research and
Forecast Report 2023-2028
Author: Elena Anderson,
Marketing Manager |
IMARC Group
© 2019 IMARC All Rights Reserved

2. Report Description
About IMARC Group
The International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all sectors
and regions to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Cancer Biomarkers Market Research Report:
The latest report by IMARC, titled “Cancer Biomarkers Market: Global Industry Trends, Share, Size,
Growth, Opportunity and Forecast 2023-2028” finds that the global cancer biomarkers market size
reached US$ 24.7 Billion in 2022.
Cancer biomarkers refer to biological molecules produced by the cancer cells or other cells in the body
in response to cancer. Enzymes, peptides, proteins, nucleic acids, genes, and specific cells are some of
the most commonly used biomarkers. They indicate the presence of cancer in the blood, tissues, or
other fluids of the body. They are widely used for disease diagnosis, screening, establishing prognosis,
monitoring treatment, and detecting the chances of relapse.
They also assist healthcare professionals in tracking the progression of the disease, identifying invasive
and non-invasive tumors, and recording treatment efficacy. As a result, cancer biomarkers find
extensive applications as prognostics, surrogate endpoints, diagnostics, and personalized medicines
across the healthcare industry.
Request Free Sample Report: https://www.imarcgroup.com/cancer-biomarkers-
market/requestsample

4. Report Description
Report Description and Highlights
Global Cancer Biomarkers Market Trends:
The rising incidences of cancer, such as breast, prostate, cervical, lung, and colorectal cancer, represent the primary
factor driving the market growth. Besides this, the increasing usage of cancer biomarkers in early cancer detection,
managing treatment, and predicting accurate outcomes is another major growth-inducing factor. Additionally, due to
the lack of standard diagnosis, there has been a significant shift toward personalized medicine for cancer treatment.
In line with this, the growing awareness regarding the importance of early cancer diagnosis among healthcare
professionals and patients has augmented the demand for cancer biomarkers. Furthermore, several key players are
extensively investing in research and development (R&D) activities to introduce innovative diagnostic products.
Along with this, recent technological advancements in genetic biomarker discovery, such as next-generation
sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and proteomics, have
propelled market growth. Other factors, including the rising regulatory approvals of novel drugs and diagnostics,
improving healthcare infrastructure, surging government funding for drug development, increasing consumer
healthcare spending, and availability of favorable reimbursement policies, are also providing a positive thrust to the
market growth. Looking forward, IMARC Group expects the market value to reach US$ 53.7 Billion by 2028, expanding
at a CAGR of 12.95% during 2023-2028.
Looking forward, the market value is projected to reach a strong growth during the forecast period
(2023-2028).

5. Report Description
Report Description and Highlights
Market Summary:
Breakup by Profiling Technology:
• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics
Breakup by Biomolecule:
• Genetic Biomarkers
• Protein Biomarkers
• Glyco-Biomarkers
Breakup by Cancer Type:
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Others

6. Report Description
Report Description and Highlights
Breakup by Application:
• Diagnostics
• Prognostics
• Risk Assessment
• Drug Discovery and Development
• Others
Breakup by End User:
• Hospitals
• Academic and Research Institutions
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others
Breakup by Region:
• North America
• United States
• Canada
• Asia-Pacific
• China

7. Report Description
Report Description and Highlights
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

8. Competitive Landscape with Key Players:
• Abbott Laboratories
• Agilent Technologies Inc.
• Becton Dickinson and Company
• bioMérieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• General Electric Company
• Illumina Inc.
• Qiagen N.V.
• Sino Biological Inc.
• Thermo Fisher Scientific Inc.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/cancer-biomarkers-market
Report Description
Report Description and Highlights

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us